Group 1 - The core point of the article is the approval by the China Securities Regulatory Commission for Ningbo Jianxin Superconducting Technology Co., Ltd. to conduct its initial public offering (IPO) on the Shanghai Stock Exchange, with a fundraising target of 865 million yuan [1] - Jianxin Superconducting primarily engages in the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, including superconducting magnets, permanent magnets, and gradient coils [1] - The company has developed a diverse product matrix in the superconducting field, including 1.5T zero-evaporation superconducting magnets, 1.5T liquid helium-free superconducting magnets, 3.0T zero-evaporation superconducting magnets, and open zero-evaporation superconducting magnets, making it the leading independent supplier of superconducting magnets in the global MRI industry [1]

Core Viewpoint - Ningbo Jianxin Superconductor Technology Co., Ltd. has successfully passed the IPO review for the Sci-Tech Innovation Board, positioning itself as the world's largest independent supplier of superconducting magnets for MRI equipment [1][2] Group 1: Company Overview - Jianxin Superconductor's IPO application was approved on October 21, with its review status updated to "submitted for registration" [1] - The company ranks fifth globally and second domestically in terms of market share for superconducting magnets used in MRI equipment, based on installed capacity [1] Group 2: Market Position and Technology - The company has closed a 20-year technology gap with international giants in the field of zero-evaporation superconducting technology, enhancing product performance and cost competitiveness through design and process innovation [2] - Jianxin Superconductor is one of the earliest manufacturers in China to scale up the production of high-field superconducting magnets, breaking the long-standing monopoly of European and Japanese manufacturers since 2015 [2] Group 3: Financial Performance - The company's revenue for the years 2022 to 2024 and the first half of 2025 is as follows: - 2022: 35.89 million yuan - 2023: 45.06 million yuan - 2024: 42.55 million yuan - 2025 (first half): 25.21 million yuan [2] - Net profit figures for the same periods are: - 2022: 3.46 million yuan - 2023: 4.87 million yuan - 2024: 5.58 million yuan - 2025 (first half): 3.19 million yuan [2] Group 4: Partnerships and Industry Impact - The company has established close partnerships with well-known MRI equipment manufacturers, including Fujifilm, GE Healthcare, and United Imaging Healthcare, contributing to the domestic MRI industry's core component supply [2]

Core Viewpoint - Ningbo Jianxin Superconducting Technology Co., Ltd. has received approval for its IPO application on the Sci-Tech Innovation Board, with its review status updated to "submitted for registration" as of October 21 [1] Group 1: Market Position and Competitiveness - In terms of installed capacity, Jianxin Superconducting ranks fifth globally and second among domestic companies in the MRI superconducting magnet market for 2024, making it the largest independent supplier of superconducting magnets worldwide [1] - The company has established a comprehensive product matrix in the superconducting field, including 1.5T zero-evaporation superconducting magnets and 3.0T zero-evaporation superconducting magnets, becoming the top independent supplier in the global MRI industry [3] - Jianxin Superconducting has closed a 20-year technology gap with international giants in the zero-evaporation superconducting technology field and has continuously improved product performance and cost competitiveness through design and process innovation [3] Group 2: Financial Performance - The company's revenue for the periods from 2022 to 2024 and the first half of 2025 are as follows: 358.93 million yuan, 450.64 million yuan, 425.50 million yuan, and 252.10 million yuan respectively [4] - The net profit for the same periods is reported as 34.63 million yuan, 48.73 million yuan, 55.78 million yuan, and 31.92 million yuan respectively [4] Group 3: Strategic Partnerships - Jianxin Superconducting has established close cooperative relationships with well-known MRI equipment manufacturers both domestically and internationally, including Fujifilm Holdings, GE Healthcare, and United Imaging Healthcare [3]

Core Viewpoint - The IPO application of Ningbo Jianxin Superconducting Technology Co., Ltd. has been accepted, marking it as the third company to receive approval for an IPO on the Sci-Tech Innovation Board this year, highlighting the ongoing effects of the "Sci-Tech Innovation Board Eight Articles" policy [1] Company Overview - Jianxin Superconducting is the largest independent supplier of superconducting magnets globally, breaking the monopoly of international giants in the core components of MRI [1][2] - The company aims to raise 865 million yuan through its IPO to seize industry development opportunities [1] Market Position and Competition - Jianxin Superconducting's main products, including superconducting magnets, permanent magnets, and gradient coils, account for approximately 50% of the cost of MRI equipment [3] - The MRI core component market has been dominated by international giants like GE Healthcare, Siemens Healthineers, and Philips Healthcare, which hold over 80% of the global market share [3] - Jianxin Superconducting has closed the technological gap with international competitors by about 20 years in the mainstream zero-evaporation superconducting magnet field and has transitioned from a follower to a leader in the liquid helium-free superconducting magnet sector [4] Financial Performance - The company's revenue for 2022, 2023, and 2024 is reported as 359 million yuan, 451 million yuan, and 425 million yuan respectively, with net profits of 34.63 million yuan, 48.73 million yuan, and 55.78 million yuan [4][5] Industry Growth and Opportunities - The global MRI equipment market is in a phase of technological upgrade and market expansion, with a projected growth from 11.1 billion USD in 2024 to 14.89 billion USD by 2030, reflecting a compound annual growth rate of approximately 5.0% [7] - The Chinese market is identified as the largest incremental market, with policies encouraging the procurement of domestic high-end medical equipment and increased financial subsidies for medical device R&D [9] IPO Fund Utilization - The funds raised from the IPO will be directed towards projects including the annual production of 600 sets of liquid helium-free superconducting magnets, technological upgrades for high-field medical superconducting magnets, and new superconducting magnet R&D [9][11] - The successful implementation of these projects is expected to enhance the production capacity of high-end products and solidify the company's leading position in the liquid helium-free technology sector [11]